<DOC>
	<DOCNO>NCT02046421</DOCNO>
	<brief_summary>This phase I trial study side effect best dose gemcitabine hydrochloride mifepristone give together carboplatin treat patient breast cancer metastatic remove surgery recurrent persistent ovarian epithelial , fallopian tube , primary peritoneal cancer . Drugs use chemotherapy , carboplatin gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . Steroid hormone cause growth cancer cell . Hormone therapy use mifepristone may fight breast ovarian cancer lower amount steroid hormone body make . Giving carboplatin gemcitabine hydrochloride together mifepristone may effective treatment breast , ovarian epithelial , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Carboplatin , Gemcitabine Hydrochloride , Mifepristone Treating Patients With Advanced Breast Cancer Recurrent Persistent Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) mifepristone give combination carboplatin gemcitabine ( gemcitabine hydrochloride ) . SECONDARY OBJECTIVES : I . To determine safety tolerability mifepristone combination carboplatin gemcitabine . II . To describe toxicity see carboplatin , gemcitabine , mifepristone combination therapy . TERTIARY OBJECTIVES : I . To correlate expression biomarkers ( e.g . glucocorticoid receptor [ GR ] , androgen receptor [ AR ] , estrogen receptor [ ER ] , progesterone receptor [ PR ] ) treatment outcome . II . To correlate serum intratumoral mifepristone concentration two dos mifepristone ( patient easily accessible tumor consent optional research biopsy ) . OUTLINE : This dose-escalation study mifepristone . Patients receive mifepristone orally ( PO ) daily ( QD ) day 0 , 1 , 7 , 8 , carboplatin intravenously ( IV ) 30 minute gemcitabine hydrochloride IV 30-60 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Patients eligible follow : metastatic unresectable breast cancer , recurrent persistent epithelial ovarian , fallopian tube , primary peritoneal cancer Ovarian cancer patient platinumsensitive platinumresistant disease eligible . Ovarian cancer patient platinum refractory disease ( failure achieve complete response first line platinum therapy ) ineligible . Men metastatic unresectable breast cancer eligible Patients must measurable evaluable disease ( subject elevation tumor marker evidence disease image exam eligible ) Patients breast cancer may receive neoadjuvant adjuvant chemotherapy two prior chemotherapy regimens metastatic locally recurrent disease ; subject ovarian cancer may two regimen advance persistent disease Patients ER positive ER negative breast cancer eligible study . Patients HER2 positive disease exclude participation study . Metastatic breast cancer patient hormone receptor positive baseline must hormone refractory indication emergent treatment chemotherapy ( e.g. , visceral crisis ) . Patients know brain metastasis eligible long complete radiation brain corticosteroid therapy least 2 week prior study treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( Karnofsky &gt; 60 % ) Absolute neutrophil count &gt; = 1,500/mL Platelets &gt; = 100,000/mL Total bilirubin = &lt; institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) 5 = &lt; X institutional ULN Creatinine = &lt; institutional ULN OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Morning cortisol &gt; = institutional normal If woman childbearing potential , negative serum urine pregnancy test require ; woman childbearing potential men sexually active must agree use birth control barrier method birth control , abstinence , else surgically sterile ( tubal ligation , hysterectomy partner confirm vasectomy ) prior study entry duration study participation ; hormonal contraception permit trial ; alternatively patient must postmenopausal define great 12 month without menstrual cycle ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; nurse patient must discontinue breast feed prior initiation therapy Ability understand willingness sign inform consent document Bisphosphonate ( e.g . zoledronic acid ) receptor activator nuclear transcription factor kappaB ( NFkappaB ) ligand ( RANKL ) inhibitor ( e.g . denosumab ) use bone metastasis permit Patients recovered toxicity prior therapy point would appropriate redo ineligible study treatment . All patient must two week washout period prior chemotherapy . Patients must least two week prior radiation therapy ( RT ) Patients must one week washout period prior hormonal therapy ( e.g . testosterone , estrogen , progestin , gonadotropinreleasing hormone antagonist ) Patients may receive investigational agent Mifepristone inhibit cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) induce CYP3A4 ; addition mifepristone preexist drug regimen may cause mild temporary increase plasma drug concentration drug significant CYP3A4 metabolism ; medication strong inducer CYP3A4 carbamazepine , oxcarbazepine , phenobarbital , phenytoin , primidone , rifabutin , rifampin , rifapentine , St. John 's Wort may decrease plasma mifepristone level ; strong CYP3A4 inhibitor medication expect cause large increase plasma mifepristone concentration ; mifepristone may increase plasma drug concentration concomitant medication metabolism mediate cytochrome P450 , family 2 , subfamily C , polypeptide 9 ( CYP2C9 ) /cytochrome P450 , family 2 , subfamily C , polypeptide 8 ( 2C8 ) Uncontrolled intercurrent illness include , limited , ongoing active infection , poorly control hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue patient wish participate study Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible History longterm use corticosteroid concurrent shortterm use corticosteroid allow ; shortterm corticosteroid use must discontinue least 2 week prior study treatment Prior mifepristone use anticancer therapy allow Patients advanced breast cancer receive platinum therapy ( e.g . carboplatin cisplatin ) and/or gemcitabine therapy metastatic disease exclude ( platinumbased therapy and/or gemcitabine adjuvant neoadjuvant setting allow ) Ovarian cancer patient receive prior gemcitabine therapy ineligible ; ( prior carboplatin therapy allow ) Patients know grade 2 great allergic reaction attribute compound similar chemical biologic composition mifepristone , carboplatin , gemcitabine ineligible study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>